Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toludesvenlafaxine in Generalized Anxiety Disorder
NCT05970510Phase 3Completed
- Sponsor
- Luye Pharma Group
- Start
- Aug 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of toludesvenlafaxine in generalized anxiety disorder (GAD), sponsored by Luye Pharma Group. Started Aug 2023; status: completed.
02
Drugs
toludesvenlafaxine
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT05970510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05970510.